These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30848188)

  • 1. Mineralocorticoid Receptor Antagonists in Essential and Resistant Hypertension.
    Imprialos KP; Bouloukou S; Kerpiniotis G; Katsimardou A; Patoulias D; Bakogiannis C; Faselis C
    Curr Pharm Des; 2018; 24(46):5500-5507. PubMed ID: 30848188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
    Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
    Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension.
    Bazoukis G; Thomopoulos C; Tsioufis C
    J Hypertens; 2018 May; 36(5):987-994. PubMed ID: 29356711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?
    Manolis AA; Manolis TA; Melita H; Manolis AS
    Curr Hypertens Rep; 2019 Mar; 21(3):22. PubMed ID: 30826898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists.
    Sueta D; Yamamoto E; Tsujita K
    Curr Hypertens Rep; 2020 Feb; 22(3):21. PubMed ID: 32114686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.
    Sica DA
    Methodist Debakey Cardiovasc J; 2015; 11(4):235-9. PubMed ID: 27057293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid receptor antagonism as an add-on treatment for resistant hypertension.
    Rossi GP; Maiolino G
    Hypertens Res; 2014 Dec; 37(12):1029-31. PubMed ID: 25231253
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
    Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
    Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis.
    Sinnott SJ; Tomlinson LA; Root AA; Mathur R; Mansfield KE; Smeeth L; Douglas IJ
    Eur J Prev Cardiol; 2017 Feb; 24(3):228-238. PubMed ID: 27856806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant Hypertension: A Review.
    Flatt DM; Brown MC; Mizeracki AM; King BJ; Weber KT
    JAMA Cardiol; 2016 Aug; 1(5):607-12. PubMed ID: 27434136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone: a review of its use in essential hypertension.
    Croom KF; Perry CM
    Am J Cardiovasc Drugs; 2005; 5(1):51-69. PubMed ID: 15631538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
    Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Lales G; Mitas C; Doumas M
    Curr Pharm Des; 2018; 24(46):5508-5516. PubMed ID: 30854950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension.
    Schneider A; Schwab J; Karg MV; Kalizki T; Reinold A; Schneider MP; Schmieder RE; Schmidt BM
    J Hypertens; 2017 May; 35(5):1086-1092. PubMed ID: 28118280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy of Hypertension in Chronic Dialysis Patients.
    Georgianos PI; Agarwal R
    Clin J Am Soc Nephrol; 2016 Nov; 11(11):2062-2075. PubMed ID: 27797886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.
    Colussi G; Catena C; Sechi LA
    J Hypertens; 2013 Jan; 31(1):3-15. PubMed ID: 23011526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension.
    Narayan H; Webb DJ
    Curr Hypertens Rep; 2016 Apr; 18(5):34. PubMed ID: 27072827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
    George J; Struthers AD
    Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.
    Ghazi L; Dudenbostel T; Lin CP; Oparil S; Calhoun DA
    J Hypertens; 2016 May; 34(5):1005-10. PubMed ID: 26886564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistant hypertension. What is the best approach?
    Barrios V; Escobar C
    Rev Esp Cardiol; 2009 Jun; 62(6):711-2; author reply 712. PubMed ID: 19480775
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.